Form 8-K - Current report:
SEC Accession No. 0001159036-24-000049
Filing Date
2024-10-31
Accepted
2024-10-31 16:05:56
Documents
16
Period of Report
2024-10-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K halo-20241031.htm   iXBRL 8-K 32749
2 EX-99.1 ex991q320248-k.htm EX-99.1 199078
6 GRAPHIC halo-20241031_g1.jpg GRAPHIC 15840
7 GRAPHIC halozymea23a.jpg GRAPHIC 701236
  Complete submission text file 0001159036-24-000049.txt   1346248

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT halo-20241031.xsd EX-101.SCH 1798
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT halo-20241031_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT halo-20241031_pre.xml EX-101.PRE 12522
18 EXTRACTED XBRL INSTANCE DOCUMENT halo-20241031_htm.xml XML 2712
Mailing Address 12390 EL CAMINO REAL SAN DIEGO CA 92130
Business Address 12390 EL CAMINO REAL SAN DIEGO CA 92130 (858) 794-8889
HALOZYME THERAPEUTICS, INC. (Filer) CIK: 0001159036 (see all company filings)

EIN.: 880488686 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32335 | Film No.: 241415233
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)